Kersey J H, LeBien T W, Hurwitz R, Nesbit M E, Gajl-Peczalska K J, Hammond D, Miller D R, Coccia P F, Leikin S
Am J Clin Pathol. 1979 Oct;72(4 Suppl):746-52.
Results are reported on 724 children and adolescents with acute leukemia-lymphoma. One hundred patients had immunologic marker analysis that defined the major phenotypic groups, i.e., T-cell, B-cell (Burkitt), myeloid, and the most frequent form, non-T, non-T "common" or "undifferentiated" acute leukemia. Pre-T, pre-B, and "null" leukemias are included in the latter group. Response to therapy and survival was best in non-T, non-B acute lymphocytic leukemia, intermediate in T-cell disease, and worst in B-cell (Burkitt) disease. Additional factors resulting in decreased survival include elevated peripheral leukocyte count, presence of enlarged nodes, less depression of hemoglobin and platelets, and age greater than 7 years (all associated with 'lymphomatous" disease). Other factors resulting in decreased survival include age under 3 years and depression of serum immunoglobulins. Definition of the heterogeneity of childhood leukemia-lymphoma dictates differing forms of therapy for the various types of these diseases.
报告了724例儿童和青少年急性白血病-淋巴瘤患者的结果。100例患者进行了免疫标志物分析,确定了主要的表型组,即T细胞、B细胞(伯基特)、髓系,以及最常见的形式,非T、非B“普通”或“未分化”急性白血病。前T、前B和“无”白血病包含在后一组中。非T、非B急性淋巴细胞白血病对治疗的反应和生存率最佳,T细胞疾病居中,B细胞(伯基特)疾病最差。导致生存率降低的其他因素包括外周白细胞计数升高、出现肿大淋巴结、血红蛋白和血小板降低程度较小以及年龄大于7岁(均与“淋巴瘤样”疾病相关)。导致生存率降低的其他因素包括3岁以下年龄和血清免疫球蛋白降低。儿童白血病-淋巴瘤异质性的定义决定了针对这些疾病不同类型的不同治疗形式。